Adherium
Adherium (ASX: ADR) is an Australian digital health company that sells the FDA-cleared Hailie Smartinhaler platform—Bluetooth inhaler sensors plus a cloud data and RPM platform—for remote monitoring of medication adherence in asthma and COPD patients, serving US health systems, payers, specialty respiratory networks, and pharmaceutical clinical trials.
- Company typePublic
- Founded2001
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Adherium does
Adherium Limited (ASX: ADR) is an Australian digital health company founded in 2001 and listed on the ASX in 2015, focused on remote monitoring of inhaled medication adherence for asthma and COPD patients. The company's core product is the Hailie Smartinhaler platform—FDA-cleared Bluetooth-enabled sensors that attach to inhaler devices (pMDIs, Diskus, Respimat, HandiHaler, Turbuhaler, Ellipta), paired with a regulatory-compliant cloud data platform, a patient mobile app, and a clinical/customer portal. Adherium holds an extensive patent portfolio covering sensor designs across major inhaler types and FDA clearances for use with inhalers from AstraZeneca (Airsupra, Breztri, Symbicort/Vannair), GSK (Ellipta), and Teva (ProAir); the company has shipped over 180,000 devices across 30 countries and claims the most clinically supported respiratory adherence solution on the market (>85 studies, 13,000+ patients, >100 peer-reviewed publications).
The business model centres on three revenue streams: recurring Remote Patient Monitoring (RPM) subscriptions in the US under favorable CPT reimbursement codes (~$1,400/patient/year to physicians), clinical trial sensor contracts with pharmaceutical companies and CROs, and one-time device sales. In H1 FY2026, revenue decomposed to A$278,783 from RPM subscriptions (up 103% QoQ), A$192,000 from clinical trial contracts, and A$76,075 from device sales, totalling A$801,402 and reflecting 60% YoY growth. Adherium sells primarily through direct enterprise sales to US health systems, payers, and specialty respiratory networks, supplemented by channel partnerships with Monaghan Medical Corporation for US distribution and integrated deployments with Allergy Partners (110+ clinic locations), HGE Health, SENTA Partners, and Intermountain Health (iCARE program). Management targets 10,000 RPM device shipments by end of FY2026 against a verified pipeline of 40,000 eligible patients.
The company employs 51-100 staff across Melbourne (corporate HQ at Level 5, 447 Collins Street; R&D with Planet Innovation), Auckland (regional HQ), and operates through wholly-owned subsidiaries in the US (Adherium North America, Inc.), the UK (Adherium Europe Ltd), and New Zealand (Adherium (NZ) Limited). Leadership was substantially refreshed in 2025-2026 to support US scaling: Dawn Bitz was appointed CEO in July 2025, John Perry joined as Chief Commercial Officer in June 2026, and the board was reconstituted with Trudell Medical's George Baran as Non-Executive Chair and BioScience Managers' Victoria Durrans as Director. The company has been funded through repeated post-IPO equity raises (notably A$8.37M in April 2024 and A$6.7M institutional plus up to A$0.82M retail in February 2026) and has secured alliances with life-sciences VC BioScience Managers as a major shareholder.
Adherium firmographics
Firmographics- Name
- Adherium
- Legal name
- Adherium Limited
- Website
- https://adherium.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Adherium (ASX: ADR) is an Australian digital health company that sells the FDA-cleared Hailie Smartinhaler platform—Bluetooth inhaler sensors plus a cloud data and RPM platform—for remote monitoring of medication adherence in asthma and COPD patients, serving US health systems, payers, specialty respiratory networks, and pharmaceutical clinical trials.
- Ownership category
- akta.pro rank
Adherium industry classification
Industry- Product category
- Remote Patient Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- akta.pro primary industry
- Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH)
Keywords
Where Adherium is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Adherium business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure, Supply Chain
Revenue model
- Remote Patient Monitoring (RPM) Subscriptions: Recurring Remote Patient Monitoring subscription revenue from US healthcare market. Management reports A$278,783 in RPM subscriptions for first-half FY26, with quarterly growth of 103% quarter-on-quarter. CPT codes enable physician billing of approximately $1,400 per patient annually.
- Clinical Trial Contracts: Revenue from clinical trial sensor and software supply contracts. First-half FY26 revenue of A$192,000 from clinical trial contracts.
- Device Sales: One-time device sales of Hailie Smartinhaler sensors. First-half FY26 revenue of A$76,075 from device-only sales. 4,666 devices delivered in CY2025 including 2,034 RPM devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | RPM subscription model with per-patient recurring revenue |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Adherium product offering
Product offeringCore offering
Adherium sells the Hailie® Smartinhaler® platform, consisting of FDA-cleared Bluetooth-enabled sensors that attach to patients' inhaled medication devices, a companion mobile application, and a cloud-based data management infrastructure. The integrated Hailie RPM Platform enables physicians and payers to remotely monitor medication adherence, generate CPT-code compliant reimbursement reports, and manage difficult-to-treat asthma and COPD patients across US health systems, specialty networks, and pharmaceutical clinical trials.
Product overview
Adherium's Hailie® Smartinhaler® is a unified digital respiratory medication adherence platform consisting of FDA-cleared Bluetooth-enabled sensors that attach to patients' existing inhalers, a companion mobile app providing real-time medication use feedback, a regulatory-compliant cloud data management infrastructure, and clinical/customer portals for reimbursement reporting. The Hailie® RPM Platform integrates these components to enable Remote Patient Monitoring reimbursement for physicians treating asthma and COPD patients, while the Smartinhaler® sensors form the core hardware component with coverage across multiple inhaler types including pMDIs and dry powder inhalers from pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Brands
- Hailie Smartinhaler: FDA-cleared Bluetooth-enabled sensors that attach to inhalers and track medication use, providing real-time feedback via the Hailie app.
- Hailie RPM Platform
- Smartinhaler
Products and services
- Hailie Smartinhaler Sensors FDA-cleared Bluetooth-enabled sensors that attach to inhaled medication devices (pMDIs, Diskus, Ellipta, Turbuhaler, HandiHaler, Respimat) and capture medication use and physiological data for asthma and COPD patients. Sold to US health systems, payers, providers, specialty respiratory networks, and pharmaceutical companies.
- Hailie App Mobile companion application that monitors medication activation, adherence and timing, providing real-time feedback to patients on their medication use patterns. Available on iOS and Android.
- Hailie Data Management Platform Regulatory-compliant cloud infrastructure for secure storage and management of patient medication use data, with proprietary algorithms generating auditable reimbursement reports for payers and providers. Supports future data and freemium service capabilities.
- Hailie Portal Clinical portal providing reimbursement-compliant reports, billing support, and audit trail for healthcare providers and payers. Powers CPT-coded RPM billing workflows for asthma and COPD patient management.
- Hailie RPM Platform Comprehensive Remote Patient Monitoring (RPM) platform integrating Hailie sensors, mobile app, cloud data management and clinical portal to enable physician reimbursement through US CPT codes (approximately $1,400 per patient annually) for respiratory medication adherence monitoring. Sold under recurring subscription to US health systems, payers, and specialty respiratory networks.
Quantifiable outcome
- 180% increase in adherence to preventative medication in children, 59% in adults
- +7 more outcomes
Companies that use Adherium
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Adherium technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Adherium partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor and core.
- VRIminorStrategic partnership for respiratory care solutions.
- NuvoAir MedicalminorPartnership to enhance patient outcomes through respiratory monitoring integration.
- Allergy PartnerscoreMajor asthma partnership for RPM program rollout. Allergy Partners is one of the largest allergy and asthma networks in US with 110+ clinic locations serving 90,000+ asthma patients. Adherium manages end-to-end activation of patients onto fee-for-service RPM workflow.
- AvillionminorCollaboration to support Avillion-sponsored clinical study using Hailie Smartinhaler technology.
- Planet InnovationcoreStrategic device hardware and software development partnership to enhance Adherium's leading device coverage position in both asthma and COPD. Planet Innovation supports development of next-generation sensors with enhanced physiological measurement capabilities. Planet Innovation has proven track record in highly regulated medical device hardware and software development.
- HGE HealthcoreUS disease management collaboration for COPD with HGE Health's telemedicine platform integration. HGE Health's clinically-validated algorithms assess medication adherence allowing effectiveness evaluation on patient-by-patient basis. Collaboration focuses on COPD patients with plans to extend to asthma management.
- Monaghan Medical CorporationcoreMonaghan Medical Corporation partnership provides Adherium with access to targeted facilities across the US through strong customer relationships. Monaghan is dedicated to improving lives of people with respiratory conditions, and the partnership brings Hailie platform to complement their current product offering and expand into digital space.
- Intermountain HealthcoreIntermountain Health iCARE respiratory program - one of the largest real-world respiratory monitoring programs. Combined Hailie Smartinhalers with connected monitoring devices, AI-driven behavioural engagement and clinical care oversight. Demonstrated 235% adherence improvement, 53% inpatient admission reduction.
- SENTA PartnerscoreMajor asthma partnership with US-based SENTA partners for patient enrollment program in US market. Focus on uncontrolled, paediatric and adult asthma patients with high burden of disease and healthcare costs in secondary/tertiary care.
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
Adherium competitors and assessment
Company assessmentEmerging players
- Tenovi: RPM hardware and cellular gateway provider integrating with multiple chronic disease management platforms; Adherium technology integration partner. Comparable as an enabler of RPM programs that competes for the same health system/payer deployment slots.
- Rimidi: Respiratory clinical management platform integrated with EHR systems; Adherium technology partner. Comparable as a respiratory-focused RPM platform competing for similar health system and specialty practice customers.
- AMC Health: US RPM and virtual care provider offering chronic disease management including COPD; Adherium technology integration partner. Comparable as a broader RPM provider addressing similar payer and health system contracts.
- NuvoAir Medical: Digital respiratory care platform providing virtual pulmonary rehabilitation, RPM, and chronic condition management. Comparable as an emerging respiratory-focused RPM player addressing the same difficult-to-treat asthma/COPD populations with payer-facing value-based care models.
Direct peers
- Propeller Health: Direct competitor in connected inhaler sensors and respiratory RPM; acquired by ResMed in 2019. Most direct comparison for Adherium's Hailie Smartinhaler, targeting the same asthma/COPD adherence use case with similar Bluetooth sensor hardware.
- Aptar Pharma: Drug delivery device manufacturer (pMDIs, DPIs, nasal) supplying pharmaceutical companies globally. Comparable as a developer and manufacturer of inhaler-compatible digital health/drug delivery platforms serving the same asthma/COPD patient population.
- HGE Health: US COPD disease management company with telemedicine platform; active commercial partner of Adherium. Comparable as a respiratory RPM/disease management competitor covering overlapping COPD patient populations in the US payer/provider market.
Broad incumbents
- AstraZeneca: Major respiratory pharma manufacturer of Airsupra, Breztri, and Symbicort (all Adherium-cleared inhalers). Comparable as a pharma partner whose broader digital respiratory strategy and potential internal smart-inhaler development directly affects Adherium's addressable market.
- GSK: Major respiratory pharma manufacturer of Ellipta inhaler products (Hailie-cleared). Comparable as a pharma incumbent whose digital respiratory investments and inhaler portfolio strategy shape Adherium's market positioning.
- ResMed: Global leader in sleep apnea and respiratory care devices; parent of Propeller Health. Comparable as a broader respiratory medical device incumbent that now competes directly in connected inhaler RPM via Propeller and adjacent digital health capabilities.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Adherium social profiles
Digital presenceAdherium compliance and trust
Trust signalCompliance5 records
Adherium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adherium leadership team
Management profileNumber of profiles
Profiles12 records
Adherium subsidiaries and ownership
Company hierarchySubsidiaries3 records
Adherium funding detail
Funding detailFunding overview
Funding rounds9 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adherium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adherium
What does Adherium do?
Adherium sells the Hailie® Smartinhaler® platform, consisting of FDA-cleared Bluetooth-enabled sensors that attach to patients' inhaled medication devices, a companion mobile application, and a cloud-based data management infrastructure. The integrated Hailie RPM Platform enables physicians and payers to remotely monitor medication adherence, generate CPT-code compliant reimbursement reports, and manage difficult-to-treat asthma and COPD patients across US health systems, specialty networks, and pharmaceutical clinical trials.
Is Adherium a public or private company?
Adherium is a public company. It is classified as public and is currently operating.
When was Adherium founded?
Adherium was founded in 2001. It employs 11 to 50 people.
Where is Adherium based?
Adherium is headquartered in Melbourne, Australia, in the Oceania region.
How does Adherium make money?
Three revenue lines are on record. Remote Patient Monitoring (RPM) Subscriptions are the primary driver. The others are clinical Trial Contracts and device Sales.
Who are Adherium's main competitors?
Emerging players on record are Tenovi, Rimidi, AMC Health and NuvoAir Medical. Direct peers are Propeller Health, Aptar Pharma and HGE Health. Broad incumbents are AstraZeneca, GSK and ResMed.
Does Adherium have an API?
No public API is recorded for Adherium.
What industry is Adherium in?
Adherium's product category is Remote Patient Monitoring. Its primary akta.pro industry code is HLACAPAH, Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers). Its NAICS code is 334510.